The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.
The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.
复制标题
CRH1 受体非肽拮抗剂 CP-154,526 的药理学：综述。
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
D. Schulz
中科院分区：
文献类型：
--
作者：
P. Seymour;Anne W. Schmidt;D. Schulz
Since CRH has been shown to mediate stress-induced physiological and behavioral changes, it has been hypothesized that CRH receptor antagonists may have therapeutic potential in disorders that involve excessive CRH activity. CP-154,526 and its close analog antalarmin are potent, brain-penetrable, selective nonpeptide CRH1 receptor antagonists that were discovered in an effort to develop compounds with efficacy in CNS disorders precipitated by stress. Since its discovery many investigators have used CP-154,526 as a tool to study the pharmacology of CRH and its receptors and to evaluate its therapeutic potential in a variety of CNS and peripheral disorders. Systemically-administered CP-154,526 has been demonstrated to antagonize CRH- and stress-induced neuroendocrine, neurochemical, electrophysiological, and behavioral effects. These findings support the hypothesis that CRH1 receptor antagonists may have therapeutic utility in a number of neuropsychiatric disorders. CP-154,526, as well as other CRH1 receptor antagonists that have since been discovered, have also shown activity in several preclinical models of anxiety, depression, and substance abuse, while having little effect on locomotor activity and motor function. Although these effects are on occasion inconsistent among different laboratories, clinical evaluation of CRH1 antagonists appears justified on the basis of these and clinical data implicating the involvement of CRH in several CNS disorders. The effects of CRH1 antagonists on cognition, neurodegeneration, inflammation, and the gastrointestinal system have not been as extensively characterized and additional studies will be necessary to evaluate their therapeutic potential in these areas.
登录
查看更多内容
影响因子：
4.8
作者：
M. Perrin;Cynthia J. Donaldson;Ruoping Chen;K. Lewis;W. Vale
通讯作者：
M. Perrin;Cynthia J. Donaldson;Ruoping Chen;K. Lewis;W. Vale
DOI：
10.1073/pnas.92.7.2969
发表时间：
1995-03-28
影响因子：
11.1
作者：
PERRIN, M;DONALDSON, C;VALE, W
通讯作者：
VALE, W
外周尿皮质素延迟胃排空：CRF 受体 2 的作用。
DOI：
10.1152/ajpgi.1999.276.4.g867
发表时间：
1999
期刊：
The American journal of physiology
影响因子：
--
作者：
Nozu,T;Martinez,V;Rivier,J;Taché,Y
通讯作者：
Taché,Y
长期服用非肽 CRH 1 型受体拮抗剂安塔拉明不会减弱下丘脑-垂体-肾上腺轴对急性固定应激的反应。
影响因子：
6.1
作者：
Wong,ML;Webster,EL;Spokes,H;Phu,P;Ehrhart-Bornstein,M;Bornstein,S;Park,CS;Rice,KC;Chrousos,GP;Licinio,J;Gold,PW
通讯作者：
Gold,PW
影响因子：
--
作者：
Peter Stenzel;R. A. Kesterson;Wendy Yeung;R. Cone;Marvin B. Rittenberg;M. Stenzel-Poore
通讯作者：
Peter Stenzel;R. A. Kesterson;Wendy Yeung;R. Cone;Marvin B. Rittenberg;M. Stenzel-Poore